RepliCel Life Sciences Profit Margin

The latest profit margin for REPCF is -25.5% as of December 2024. That compares with -88.35% in the prior-year period — up 71.1% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside RepliCel Life Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, REPCF's profit margin moved from -88.35% to -25.5% — a 71.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in RepliCel Life Sciences's valuation or profitability profile.

Against Healthcare companies, REPCF currently prints -25.5% for profit margin, while the sector average sits near 10.58%. That is roughly 341.0% below the sector mean. Large gaps often invite a closer look at RepliCel Life Sciences's growth, margins, and balance sheet.

Profit Margin shows how effectively RepliCel Life Sciences converts resources into returns. At -25.5%, REPCF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -88.35% in the prior-year period — up 71.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting REPCF's profit margin (-25.5%), review year-over-year change from -88.35%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.